Wedbush Forecasts Increased Earnings for Avalo Therapeutics

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Wedbush raised their Q2 2025 earnings per share estimates for shares of Avalo Therapeutics in a research note issued to investors on Thursday, March 20th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($1.25) per share for the quarter, up from their previous forecast of ($1.40). Wedbush currently has a “Outperform” rating and a $18.00 price objective on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. Wedbush also issued estimates for Avalo Therapeutics’ Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($0.94) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($1.40) EPS.

AVTX has been the subject of a number of other research reports. Piper Sandler began coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective for the company. HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Finally, BTIG Research began coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They issued a “buy” rating and a $40.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.33.

Avalo Therapeutics Price Performance

NASDAQ:AVTX opened at $7.63 on Monday. The firm has a fifty day simple moving average of $7.47 and a 200 day simple moving average of $9.13. Avalo Therapeutics has a 1-year low of $4.60 and a 1-year high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

Several large investors have recently modified their holdings of AVTX. Tower Research Capital LLC TRC boosted its holdings in shares of Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after buying an additional 3,754 shares during the period. Marshall Wace LLP acquired a new stake in Avalo Therapeutics during the fourth quarter worth approximately $114,000. Walleye Capital LLC acquired a new stake in Avalo Therapeutics during the fourth quarter worth approximately $145,000. Northern Trust Corp bought a new stake in shares of Avalo Therapeutics during the fourth quarter worth approximately $168,000. Finally, Bank of Montreal Can acquired a new position in shares of Avalo Therapeutics in the fourth quarter valued at approximately $446,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.